Back to Search
Start Over
Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
- Source :
- Nefrología (English Edition), Vol 40, Iss 1, Pp 46-52 (2020)
- Publication Year :
- 2020
- Publisher :
- Elsevier, 2020.
-
Abstract
- Background and aims: The advent of direct-acting antiviral agents promises to change the management of hepatitis C virus infection (HCV) in patients with chronic kidney disease (CKD), a patient group in which the treatment of hepatitis C was historically challenging. We investigated the safety and efficacy of all-oral, interferon-free direct-acting antiviral agents for the treatment of hepatitis C in a ‘real-world’ cohort of patients with CKD. Methods: We performed an observational single-arm multi-centre study in a large (n = 198) cohort of patients with stage 1–3 CKD who underwent antiviral therapy with DAAs for the treatment of HCV. The primary end-point was sustained virologic response (serum HCV RNA
- Subjects :
- Diseases of the genitourinary system. Urology
RC870-923
Subjects
Details
- Language :
- English
- ISSN :
- 20132514
- Volume :
- 40
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nefrología (English Edition)
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.8e6868772d4fc4813be8aa3829b50f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.nefroe.2019.03.014